Jpmorgan Chase & CO Cybin Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Cybin Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 305 shares of CYBN stock, worth $2,702. This represents 0.0% of its overall portfolio holdings.
Number of Shares
305
Previous 1,034
70.5%
Holding current value
$2,702
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding CYBN
# of Institutions
101Shares Held
270MCall Options Held
0Put Options Held
0-
Deep Track Capital, LP Greenwich, CT58.1MShares$515 Million0.52% of portfolio
-
Ra Capital Management, L.P. Boston, MA44MShares$390 Million0.18% of portfolio
-
Logos Global Management LP San Francisco, CA40MShares$354 Million1.01% of portfolio
-
Avidity Partners Management LP Dallas, TX34.9MShares$309 Million0.46% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L325.6MShares$227 Million1.01% of portfolio
About CYBIN INC.
- Ticker CYBN
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 166,120,000
- Market Cap $1.47B
- Description
- Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to t...